Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Novel peptide agonists, favoring galanin receptor type 2 over galanin receptor type 1 and 3
Stockholm University, Faculty of Science, Department of Neurochemistry.
Stockholm University, Faculty of Science, Department of Neurochemistry.
Stockholm University, Faculty of Science, Department of Neurochemistry.ORCID iD: 0000-0001-6107-0844
2009 (English)In: The FEBS Journal, ISSN 1742-464X, E-ISSN 1742-4658, Vol. 276, 164-164 p.Article in journal, Meeting abstract (Refereed) Published
Abstract [en]

The galanin peptide family and its three receptors have with compelling evidence been implicated in a variety of human disorders. The co-localization with other neuromodulators and the distinct up-regulation during and after pathological disturbances has drawn attention to this neuropeptide family although, so far, no therapeutics have emerged past the animal model stage. In the current study we present data on receptor binding and functional response from novel galanin receptor type 2 (GalR2) selective chimeric peptides, including the M1145 peptide which show more than 90-fold higher affinity for galanin receptor type 2 over galanin receptor type 1 and a 76-fold higher affinity over galanin receptor type 3. Furthermore, the peptide produces an agonistic effect in vitro seen as an increase in inositol phosphate (IP) accumulation, both in the absence or the presence of galanin. The peptide design with a N-terminal extension of galanin(2-13), prevails new insights in the assembly of novel subtype specific ligands for the galanin receptor family. Preliminary data on peptides further exploring the usage of N-terminal extension shows even higher preferentiality towards the GalR2 and opens new possibilities to clarify the galanin system as a putative drug target.

Place, publisher, year, edition, pages
2009. Vol. 276, 164-164 p.
National Category
Biochemistry and Molecular Biology
Research subject
Neurochemistry with Molecular Neurobiology
Identifiers
URN: urn:nbn:se:su:diva-45997DOI: 10.1111/j.1742-4658.2009.07049.xOAI: oai:DiVA.org:su-45997DiVA: diva2:370826
Conference
34th Congress of the Federation-of-European-Biochemical-Societies, July 04-09, 2009, Prague, Czech Republic
Note

Special Issue: Abstracts of the 34th FEBS Congress

Available from: 2013-01-07 Created: 2010-11-18 Last updated: 2017-12-12Bibliographically approved

Open Access in DiVA

Poster FEBS(1732 kB)62 downloads
File information
File name FULLTEXT02.pdfFile size 1732 kBChecksum SHA-512
cc26e439a5b6ab0c1e2e1dcb7637f783d76f62fb899fb9e932a24d2ef7a5c96b5f3059cd515759c1c1a785e8fd51fe7a2acb05062ac38593d5c1dd1b4b5f17d0
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Runesson, JohanLangel, Ülo
By organisation
Department of Neurochemistry
In the same journal
The FEBS Journal
Biochemistry and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 62 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 40 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf